These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 8645745)

  • 1. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.
    Irigoyen MB; Primiani L; Felippo M; Candela M; Bianco RP; De Bracco MM; Galassi N
    Haemophilia; 2011 Mar; 17(2):267-74. PubMed ID: 21070488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
    Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
    J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay.
    Mondorf W; Ehrenforth S; Vigh Z; Last J; Tippmann G; Kreuz W; Scharrer I
    Vox Sang; 1994; 66(1):8-13. PubMed ID: 8146988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
    Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients.
    Reding MT; Lei S; Lei H; Green D; Gill J; Conti-Fine BM
    Thromb Haemost; 2002 Oct; 88(4):568-75. PubMed ID: 12362225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
    Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
    J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII.
    Green D; Blanc J; Foiles N
    J Lab Clin Med; 1999 Mar; 133(3):260-4. PubMed ID: 10072258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human hybridoma clones isolated from hemophilia patients with specificity for different domains of coagulating factor VIII.
    Gharagozlou S; Ghods R; Bahrami ZS; Roohi A; Jeddi-Tehrani M; Conti-Fine BM; Sharifian RA; Rabbani H; Shokri F
    Hum Antibodies; 2003; 12(3):67-76. PubMed ID: 14646035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.
    Ling M; Duncan EM; Rodgers SE; Street AM; Lloyd JV
    J Thromb Haemost; 2003 Dec; 1(12):2548-53. PubMed ID: 14675091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals.
    Algiman M; Dietrich G; Nydegger UE; Boieldieu D; Sultan Y; Kazatchkine MD
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3795-9. PubMed ID: 1570298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services.
    Oudat R; Al-Maharmeh M; Al-Ghrayeb R; Ogeilat T; Mustafa MK
    Med Arch; 2020 Jun; 74(3):187-190. PubMed ID: 32801433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of anti-factor VIII antibodies in human plasma.
    Krudysz-Amblo J; Parhami-Seren B; Butenas S; Brummel-Ziedins KE; Gomperts ED; Rivard GE; Mann KG
    Blood; 2009 Mar; 113(11):2587-94. PubMed ID: 19144987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired haemophilia syndrome: pathophysiology and therapy.
    Elezović I
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.